Piper Sandler Maintains Overweight on AbCellera Biologics, Raises Price Target to $20

Benzinga · 3d ago
Piper Sandler analyst Allison Bratzel maintains AbCellera Biologics (NASDAQ:ABCL) with a Overweight and raises the price target from $12 to $20.